The effect of berberine on the symptoms of patients with schizophrenia

The effect of berberine alkaloid on positive and negative symptoms in patients with schizophrenia: a randomized placebo-controlled double-blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190726044339N1

Enrollment

Registered

2020-12-12

Start date

2020-12-05

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Risperson 2 to 6 mg daily with one berberine capsule daily for a month. Intervention 2: Control group: Risperson 2 to 6 mg daily with one placebo capsule daily for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having schizophrenia Received antipsychotic medication in the last three months

Exclusion criteria

Exclusion criteria: Having other psychiatric disorder Pregnancy and lactation Receive concomitant ECT

Design outcomes

Primary

Measure	Time frame
Change in PANSS questionnaire score (positive and negative symptom scale). Timepoint: One month. Method of measurement: PANSS( positive and negative symptom scale).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Ghorban Nejad

Shiraz University of Medical Sciences

hamdi_88114@yahoo.com+98 71 3228 9601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026